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Minimal inhibitory and minimal fungicidal concentrations of caspofungin were determined for 48 Candida
inconspicua isolates. By using CLSI (formerly NCCLS) methodology with the partial inhibition endpoint
criterion, caspofungin exhibited a good fungicidal effect against C. inconspicua (the MIC90 was 0.25 g/ml and
the minimum fungicidal concentration [MFC] was 0.5 g/ml after 24 h). Total inhibition yielded falsely
elevated MICs, exceeding even the respective MFCs.
Caspofungin is an echinocandin antifungal exhibiting good
in vitro activity against the majority of Candida spp., including
C. krusei (4). Caspofungin MICs for Candida spp. determined
by broth microdilution (BMD) strongly depend on the applied
test conditions, such as incubation time, culture medium, and
endpoint criterion (1, 11). According to Bartizal and Odds (1),
lower caspofungin MICs could be obtained by using antibiotic
medium 3 than with RPMI medium. Pfaller et al. (11) dem-
onstrated that discrepant MIC results obtained with antibiotic
medium 3 and RPMI 1640 disappear when 24 h of incubation
and the partial inhibition endpoint criterion are used. A higher
concentration of starting inoculum seems to be less important;
Chryssanthou and Cuenca-Estrella (3) used a 100-times-higher
concentration (105 CFU/ml) of starting inoculum in their mod-
ified BMD together with a 24-h incubation time and total or
nearly total (95%) inhibition as the endpoint criterion. They
obtained 96 to 100% agreement with the standard BMD
method (9).
Caspofungin exhibits a rapid fungicidal effect against Can-
dida species, which has been proven by flow cytometry (4). A
standard method for the determination of the minimum fun-
gicidal concentration (MFC) has not yet been proposed (10),
although Canto´n et al. (2) recently described a method which
seems reliable to detect the 99.9% killing rate caused by
amphotericin B in the case of Candida species. Similar exper-
iments determining caspofungin MFCs have not yet been per-
formed (10).
C. inconspicua was the sixth most frequent Candida species
in our laboratory in 2002 (L. Majoros, G. Kardos, C. Miszti, J.
Szabo´, and B. Szabo´, Abstr. 23rd Int. Spec. Symp. Yeast, abstr.
O-6-05, 2003), and due to its decreased susceptibility to flu-
conazole, it represents a therapeutic problem. The aim of this
study was to examine the in vitro efficacy of caspofungin
against fluconazole-resistant clinical isolates of C. inconspicua
by using the standard BMD method (9) and Etest. In the BMD
test, MICs were determined by using partial inhibition and
total inhibition endpoint criteria after either 24 or 48 h incu-
bation. We also determined MFCs to C. inconspicua clinical
isolates by using the method described by Canto´n et al. (2) with
modifications (see below).
We used the same 48 clinical isolates of C. inconspicua as in
our previous study (8). The identification of isolates was per-
formed as described earlier (7). The testing of isolates was
performed in duplicate, and all tests were repeated at least
twice with each method. For interpretation, we used the break-
point proposed by Stone et al. (12): isolates with MICs of 1
g/ml were considered resistant, and isolates with lower MICs
were regarded as susceptible.
BMD. The reference BMD method was performed accord-
ing to the guidelines of CLSI (formerly NCCLS) (9). Caspo-
fungin (Merck Research Laboratories) was dissolved in sterile
distilled water. Stock solutions were diluted with RPMI 1640
medium (with l-glutamine but without bicarbonate) (Sigma),
supplemented with glucose (2%), and buffered to pH 7.0 with
0.165 M MOPS (morpholinepropanesulfonic acid) (Sigma).
The final concentration range of caspofungin was 0.03 to 8
g/ml.
Test plates were incubated at 35°C and read visually after 24
and 48 h. We used two endpoint criteria for MIC determina-
tion: (i) total inhibition (MICTI), the lowest concentration of
caspofungin that yielded no visible growth (a clear well); and
(ii) partial inhibition (MICPI), the lowest concentration that
produced a prominent decrease in turbidity compared to that
of the drug-free control. MICPIs read after 24 h were used as
reference MICs. Quality control strains of Candida parapsilosis
(ATCC 22019) and C. krusei (ATCC 6258) were included in
each test.
Etest. Caspofungin Etest strips (Merck Research Laborato-
ries) were applied to RPMI 1640 agar with 2% glucose and
buffered to pH 7.0 with MOPS. The plates were incubated at
35°C and read after 24 and 48 h.
MFC. For MFC determination, we used the method de-
scribed by Canto´n et al. (2) with the following modifications.
BMD was performed using approximately 105 CFU/ml yeast
inoculum (3); otherwise, the method was according to the
CLSI guidelines (9). The content of each well containing drug
concentrations corresponding to and higher than the MICPI
read after 24 h was transferred onto drug-free Sabouraud dex-
trose agar plates. Plates were incubated at 35°C for 48 h. The
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MFC was defined as the lowest caspofungin concentration that
killed 99.9% of the final inoculum (3-log reduction). In a
repeated experiment, MICPI determination and transfer to
antifungal-free medium were performed after 48 h of incuba-
tion.
We summarize our results in Table 1. Caspofungin demon-
strated excellent activity (48/48 susceptible) against clinical
isolates of C. inconspicua when we used the partial inhibition
criterion read at 24 and 48 h (MIC range, 0.06 to 0.25 and 0.12
to 0.5 g/ml, respectively). MICTIs obtained after both 24- and
48-h incubation tended to be higher (generally with two dilu-
tions) than the MICPI read at 24 h. Our findings are concor-
dant with the results published by Pfaller et al. (11), who
demonstrated one- to two-dilutions-higher caspofungin MICs
by using the total inhibition endpoint criterion than MICs
obtained using partial inhibition in the case of Candida albi-
cans.
The Etest provided clearly readable sharp interception
zones; growth of microcolonies was never observed. MICs ob-
tained by Etest read at 24 h were similar to the MICs found
with the BMD method that were read at 24 h (MIC range, 0.12
to 0.5 g/ml).
Comparing the MICs obtained with the methods mentioned
above to our reference MICs (partial inhibition and evaluation
at 24 h), good agreement was observed only with the MICPIs
read at 48 h and with the Etest results read at 24 h (Table 1).
Comparing MICs obtained with total inhibition endpoint cri-
terion read at 48 h, Etest MICs read at 24 and 48 h showed
only 39.6 and 60.4% agreement, respectively. Similarly, Laver-
diere et al. (6) and Chryssanthou and Cuenca-Estrella (3)
obtained good agreement between the standard BMD method
(total inhibition and 48 h incubation) and Etest only when they
defined agreement less stringently at 2 dilutions.
After 24- and 48-h incubations using high inoculum size (105
CFU/ml) and partial inhibition, MICs were the same or one
dilution higher than the MICPIs read at 24 h, in accordance
with previously described findings (3).
The MFC range of caspofungin after 24 h incubation was
0.12 to 1 g/ml (90% MFC [MFC90], 0.5 g/ml). The MFC was
equal to 1 or 2 MICPI in the cases of 83.3% (40/48) of the
isolates and never exceeded 4 MIC.
After a 48-h incubation, the obtained MFCs were lower
(0.12 to 0.25 g/ml; MFC90, 0.25 g/ml), apparently due to the
longer exposure. MFCs were equal to the MICPIs read at 24 h,
with the exception of five isolates, for which MFCs were 2
MICPI.
Agreement between the MICTI at 48 h and MFC at 24 h
within 1 dilution was only 45.8%. MFCs, with the exception
of two isolates, did not reach the MICTI read at 48 h. The
correlation between the MICTI at 48 h and the MFC at 48 h
was similarly poor. These findings suggest that after 24-h in-
cubation, virtually all cells are unviable in the wells showing
partial inhibition.
This assumption is supported by the findings of Klepser et al.
(5), who demonstrated by using scanning electron microscopy
that yeast cells exposed to a concentration greater than the
MIC80 of another echinocandin, LY303366, exhibited substan-
tial ultrastructure abnormalities and lack of viability signs. Sim-
ilarly, we proved by using transmission electron microscopy
that in the case of the total inhibition endpoint criterion, the
falsely elevated MICs (MIC90, 1 g/ml) were caused by unvi-
able cells and cell debris (data not shown). Our results, to-
gether with the findings mentioned above (5), indicate that
differences between the reference MICs and MICTIs read at
48 h are most probably due to dead yeast cells and cell debris
rather than living cells.
The good agreement between MICPI read at 24 h and MFCs
after 24 and 48 h incubation time and the inconsistency of
MFCs and MICTIs suggest that the MICTI read at either 24 h
or 48 h overestimates the MIC considerably and can frequently
lead to falsely elevated MICs, at least in the case of C. incon-
spicua. However, Pfaller et al. (11) and Bartizal and Odds (1)
similarly reported lower MICPIs than MICTIs in cases of other
species, including C. albicans, Candida glabrata, and C. krusei,
suggesting that our findings are likely to be applicable to other
Candida species as well. To confirm this assumption, further
studies are currently going on in our laboratory.
Summarizing our results, we demonstrated good in vitro
efficacy of caspofungin against the fluconazole-resistant C. in-
conspicua strains by using MICPI after a 24-h incubation. Our
results also showed that the caspofungin Etest read at 24 h may
be a reliable substitute for the BMD, at least in the case of C.
inconspicua. We found that MFCs of caspofungin correspond
well to MICPIs read after 24-h incubation but not to MICTIs
read at either 24 or 48 h. This difference was caused by trailing
wells containing mainly unviable cells.
We thank Cecı´lia Miszti and Erzse´bet Falusi for their valuable help.
Caspofungin pure powder and Etest strips were kindly provided by
Merck Research Laboratories.
REFERENCES
1. Bartizal, C., and F. C. Odds. 2003. Influences of methodological variables on
susceptibility testing of caspofungin against Candida species and Aspergillus
fumigatus. Antimicrob. Agents Chemother. 47:2100–2107.
2. Canto´n, E., J. Pema´n, A. Viudes, G. Quindo´s, M. Gobernado´, and A. Es-
TABLE 1. Distribution of caspofungin MICs and MFCs for C.
inconspicua isolates (n  48) obtained by different methods
Method or
measurement
(time in h)a
No. of isolates with
indicated MIC (g/ml) MIC50/
MIC90
MFC50/
MFC90
% Overall
agreementb
0.06 0.12 0.25 0.5 1 2
BMDPI
24 4 27 17 0 0 0 0.12/0.25
48 0 13 31 4 0 0 0.25/0.25 81.1
BMDTI
24 0 0 2 19 27 0 1/1 16.7
48 0 0 1 19 26 2 1/1 14.6
Etest
24 0 8 35 5 0 0 0.25/0.25 87.5
48 0 3 24 21 0 0 0.25/0.5 62.5
MFC
24 0 10 28 8 2 0 0.25/0.5
48 0 31 17 0 0 0 0.12/0.25
a BMDPI, broth microdilution method with partial inhibition endpoint crite-
rion; BMDTI, broth microdilution method with total inhibition endpoint crite-
rion.
b Percent agreement represents the percentage of MICs within 1 dilution of
those obtained by the reference method (9, 11).
VOL. 49, 2005 NOTES 3487
pinel-Ingroff. 2003. Minimum fungicidal concentration of amphotericin B for
bloodstream Candida species. Diagn. Microbiol. Infect. Dis. 45:203–206.
3. Chryssanthou, E., and M. Cuenca-Estrella. 2002. Comparison of the anti-
fungal susceptibility testing subcommittee on antibiotic susceptibility testing
proposed standard and the E-test with the NCCLS broth microdilution
method for voriconazole and caspofungin susceptibility testing of yeast spe-
cies. J. Clin. Microbiol. 40:3841–3844.
4. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142–1151.
5. Klepser, M. E., E. J. Ernst, M. E. Ernst, S. A. Messer, and M. A. Pfaller.
1998. Evaluation of endpoints for antifungal susceptibility determinations
with LY303366. Antimicrob. Agents Chemother. 42:1387–1391.
6. Laverdiere, M., C. Resteri, and F. Habel. 2002. Evaluation of the in vitro
activity of caspofungin against bloodstream isolates of Candida species from
cancer patients: comparison of Etest and NCCLS reference methods. Int. J.
Antimicrob. Agents 20:468–471.
7. Majoros, L., G. Kardos, A´. Bela´k, A. Mara´z, L. Asztalos, E. Csa´nky, Z.
Barta, and B. Szabo´. 2003. Restriction enzyme analysis of ribosomal DNA
shows that Candida inconspicua clinical isolates can be misidentified as
Candida norvegensis with traditional diagnostic procedures. J. Clin. Micro-
biol. 41:5250–5253.
8. Majoros, L., G. Kardos, B. Szabo´, M. Kova´cs, and A. Mara´z. 2005. Flucon-
azole susceptibility testing of Candida inconspicua clinical isolates: compar-
ison four method. J. Antimicrob. Chemother. 55:275–276.
9. National Committee for Clinical Laboratory Standards. 2002. Reference
method for broth dilution antifungal susceptibility testing of yeasts; approved
standard M27–A2. National Committee for Clinical Laboratory Standards,
Wayne, Pa.
10. Pfaller, M. A., D. J. Sheehan, and J. H. Rex. 2004. Determination of fungi-
cidal activities against yeasts and molds: lessons learned from bactericidal
testing and need for standardization. Clin. Microbiol. Rev. 17:268–280.
11. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis,
and D. J. Diekema. 2004. Further standardization of broth microdilution
methodology for in vitro susceptibility testing of caspofungin against Can-
dida species by use of an international collection of more than 3,000 clinical
isolates. J. Clin. Microbiol. 42:3117–3119.
12. Stone, E. A., H. B. Fung, and H. L. Kirschenbaum. 2002. Caspofungin: an
echinocandin antifungal agent. Clin. Ther. 24:351–357.
3488 NOTES ANTIMICROB. AGENTS CHEMOTHER.
